ArticleAnnals of hematology2024

Efficacy and safety of tixagevimab/cilgavimab as passive immunisation against COVID-19 infections in patients with hematological malignancies.

Patrick Reimann et al.PubMed ↗Publisher ↗

No numbers read from the abstract.